Editorial  New Pathways to Treat Staphylococcus aureus Bacteremia: Connecting the DOTS Erin K. McCreary, Preeti N. Malani JAMA 2025;334;(10):861-863. doi:10.1001/jama.2025.13717 Staphylococcus aureus bacteremia is a leading cause of infection-related death worldwide.1 Roughly 30% of patients who develop S aureus bacteremia will die within a year of index culture, yet relatively few randomized clinical trials have evaluated optimal antibiotic therapy.2 Con...

Alarm Fatigue Linked to Compassion Fatigue in Surgical ICUs  In ICU Tue, 14 Oct 2025 Intensive care units rely on dense constellations of monitors, ventilators and infusion devices that generate frequent alarms to protect patients. Persistent exposure to these sounds can desensitise clinicians and reduce responsiveness, a phenomenon described as alarm fatigue. In parallel, sustained emotional demands and exposure to suffering can erode the capacit...

Invited Commentary  Fecal Microbiota Transplant for Multidrug Resistance—No Benefit Without Disruption? Brendan J. Kelly, Michael H. Woodworth, Jennie H. Kwon JAMA Intern Med Published Online: April 20, 2026 doi: 10.1001/jamainternmed.2026.0668 Fecal microbiota transplant (FMT) has transformed the medical treatment of recurrent Clostridium difficile infection (R-CDI). An explosion of randomized clinical trials during the 2010s demonstrated the effectiv...

Editorial  New Lungs for Lung Cancer—Perils and Promises Ece Cali Daylan, Ramaswamy Govindan JAMA Published Online: July 8, 2026 doi: 10.1001/jama.2026.11478 Despite the recent advances in systemic therapy, survival for patients with metastatic non–small cell lung cancer (NSCLC) without actionable genomic alterations in the tumor is limited.1 A small subset of patients with NSCLC have lung-only metastatic disease and often die of progressive lung failu...

Editorial  A Multinational Trial of Rapid Antimicrobial Susceptibility Testing: Is FASTer Better? Arjun Srinivasan JAMA Published Online: April 18, 2026 doi: 10.1001/jama.2026.5504 Selecting the right antibiotic to treat an infection is the cornerstone of effective antibacterial therapy and lifesaving in severe infections.1 The growing epidemic of antimicrobial resistance is making decisions about empiric treatment increasingly difficult and elevating ...

Deep Learning Models for ICU Readmission Prediction In ICU Tue, 21 Oct 2025 The decision to discharge patients from the ICU is complex, as premature discharge increases the risk of readmission and mortality, while delayed discharge raises healthcare costs. ICU readmission is associated with over twice the mortality risk, longer hospital stays, greater morbidity, and higher resource use. Several predictive models, such as SWIFT, APACHE II and III, and S...

Invited Commentary  Health Informatics Limitations of Large Language Models in Clinical Diagnostic Reasoning Mickael Tordjman, Xueyan Mei JAMA Netw Open 2026;9;(4):e264014. doi:10.1001/jamanetworkopen.2026.4014 Large language models (LLMs) have rapidly gained an important role in multiple fields, including medicine. These widely available tools can enhance patient understanding, improve physician productivity, and provide encyclopedic knowledge on seve...

Pulmonary Haemodynamic Trajectories in ECMO-Supported ARDS In ICU Wed, 4 Mar 2026 A recent study investigated the prevalence, determinants, and prognostic implications of pulmonary hypertension (PH) in patients with acute respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane oxygenation (V-V ECMO). PH, defined as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg, is a recognised complication of ARDS and cont...

Invited Commentary  The Mechanics of Improving Compliance Meghan C. O’Leary, Jessica R. Schumacher, Gita N. Mody JAMA Surg Published Online: April 15, 2026 doi: 10.1001/jamasurg.2026.0897 We were pleased to read the report by Chan et al1 about an American College of Surgeons national quality improvement (QI) collaborative. The Lung Nodal, Operative, Dissection, Evaluation, and Staging (NODES) initiative involved a collection of multilevel interventions...

Albumin Replacement Therapy in Septic Shock In Sepsis Wed, 4 Mar 2026 The Albumin Replacement Therapy in Septic Shock (ARISS) trial, published in JAMA Network Open was designed to determine whether albumin replacement improves survival in patients with septic shock. The study was conducted on behalf of the SepNet Critical Care Trials Group and ARISS investigators. Albumin is a natural colloid with physiological roles extending beyond maintenance of ...